Outlook Therapeutics (OTLK)
NASDAQ:OTLK
Want to see OTLK full AI Analyst Report?
Top Page
Outlook Therapeutics
(NASDAQ:OTLK)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
â–˛(383.87% Upside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by very weak financial performance (deep losses, persistent cash burn, and negative equity). Offsetting this are constructive corporate/regulatory developments around the ONS-5010/LYTENAVA BLA and strong technical momentum, though overbought signals and dilution-heavy financing activity limit upside confidence.
Positive Factors
Regulatory approval pathway
A Class 1 FDA acceptance and a near-term PDUFA date materially shortens regulatory timing risk and creates a clear path to potential approval. If approved, ONS-5010 would be the first FDA-approved ophthalmic bevacizumab, a structural market shift that could secure durable commercial positioning and pricing leverage in the U.S. retina market.
Negative Factors
Negative shareholder equity
Persistently negative shareholder equity signals accumulated losses that have eroded the capital base, weakening solvency metrics and financial flexibility. Over the medium term this elevates counterparty and refinancing risk, can limit borrowing capacity, and typically forces dilutive financing or onerous terms to fund operations and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval pathway
A Class 1 FDA acceptance and a near-term PDUFA date materially shortens regulatory timing risk and creates a clear path to potential approval. If approved, ONS-5010 would be the first FDA-approved ophthalmic bevacizumab, a structural market shift that could secure durable commercial positioning and pricing leverage in the U.S. retina market.
Read all positive factors
Outlook Therapeutics (OTLK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$253.03M
Dividend YieldN/A
Average Volume (3M)32.16M
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue GrowthN/A
EPS Growth86.28%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.36
Shares Outstanding160,148,560
10 Day Avg. Volume24,275,783
30 Day Avg. Volume32,156,172
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue262.12
Enterprise Value/Gross Profit-72.64
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$0.50Price Target Upside61.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$16.01M
Outlook Therapeutics Business Overview & Revenue Model
Company Description
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010,...
How the Company Makes Money
Outlook Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it has historically generated little to no recurring product revenue because its lead asset has been in development rather than broadly co...
Outlook Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in regulatory approvals and clinical trials, along with a strong financial position. However, there were delays in the BLA resubmission timeline and increased expenses. Overall, the positive developments and strategic advancements outweigh the challenges noted.Positive Updates
Regulatory Approvals in the EU and UK
Outlook Therapeutics received marketing authorization for an ophthalmic formulation of bevacizumab for the treatment of retina diseases in the European Union and the United Kingdom.
Negative Updates
Delay in BLA Resubmission
BLA resubmission with the FDA has been pushed to the first calendar quarter of 2025 due to enrollment timelines not being met as initially anticipated.
Read all updates
Q3-2024 Updates
Positive
Negative
Regulatory Approvals in the EU and UK
Outlook Therapeutics received marketing authorization for an ophthalmic formulation of bevacizumab for the treatment of retina diseases in the European Union and the United Kingdom.
Read all positive updates
Company Guidance
During the Q3 2024 earnings call, Outlook Therapeutics provided several key updates and guidance metrics. The company announced it has received marketing authorization for its ophthalmic formulation of bevacizumab in the European Union and the United Kingdom. They are preparing for commercial launch in these regions in the first half of 2025, with ongoing market access work and inventory planning. In the United States, the NORSE EIGHT clinical trial is progressing, with 359 of the planned 400 subjects enrolled, and completion expected by the end of Q3 2024. Outlook Therapeutics anticipates top-line results from NORSE EIGHT in Q4 2024 and plans to resubmit the Biologics License Application (BLA) to the FDA in Q1 2025. Financially, the company reported a reduction in adjusted net loss and R&D expenses from the previous quarter, with a cash position of $32 million as of June 30, 2024, and expected proceeds of $107 million from the exercise of warrants, supporting operations through 2025.Outlook Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 333.14K | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.20M | 657.21K | -113.86K | -44.19K | -204.69K | -262.14K |
| EBITDA | -62.08M | -63.58M | -72.09M | -57.38M | -64.36M | -51.51M |
| Net Income | -60.96M | -62.42M | -75.37M | -58.98M | -66.05M | -53.16M |
Balance Sheet | ||||||
| Total Assets | 21.89M | 18.58M | 28.82M | 32.30M | 28.53M | 22.81M |
| Cash, Cash Equivalents and Short-Term Investments | 7.75M | 8.08M | 14.93M | 23.39M | 17.40M | 14.48M |
| Total Debt | 27.19M | 30.19M | 29.74M | 35.56M | 10.96M | 11.90M |
| Total Liabilities | 50.89M | 50.77M | 101.90M | 46.74M | 19.79M | 18.20M |
| Stockholders Equity | -28.99M | -32.19M | -73.08M | -14.44M | 8.74M | 4.61M |
Cash Flow | ||||||
| Free Cash Flow | -47.05M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Operating Cash Flow | -47.05M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Investing Cash Flow | -3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 47.24M | 44.98M | 60.33M | 48.97M | 59.59M | 56.19M |
Outlook Therapeutics Technical Analysis
Positive
0.31
Price Trends
0.51
Positive
0.44
Positive
0.87
Positive
Market Momentum
0.29
Negative
81.92
Negative
94.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLK, the sentiment is Positive. The current price of 0.31 is below the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.51, and below the 200-day MA of 0.87, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 81.92 is Negative, neither overbought nor oversold. The STOCH value of 94.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OTLK.
Outlook Therapeutics Risk Analysis
Outlook Therapeutics disclosed 75 risk factors in its most recent earnings report. Outlook Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Outlook Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $158.79M | 1.44 | 55.29% | ― | -100.00% | ― | |
53 Neutral | $186.70M | -8.46 | -48.20% | ― | 7336.90% | 49.64% | |
52 Neutral | $253.03M | -2.12 | 178.08% | ― | ― | 86.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $237.72M | -2.64 | -79.63% | ― | -100.00% | -1124.16% | |
49 Neutral | $90.73M | -14.98 | 25.68% | ― | -88.41% | 76.14% | |
41 Neutral | $21.78M | -0.21 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
OTLK
Outlook Therapeutics
1.58
-0.10
-5.95%
ORMP
Oramed Pharm
3.88
1.91
97.25%
ATRA
Atara Biotherapeutics
10.07
2.19
27.79%
WHWK
Whitehawk Therapeutics
4.42
2.47
126.67%
CELU
Celularity
0.75
-1.26
-62.59%
ADAG
Adagene
3.94
2.04
106.82%
Outlook Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA
Positive
Jun 16, 2026
On June 16, 2026, Outlook Therapeutics announced that the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for neovascular age-related macular degenera...
Product-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Resubmits FDA Application for ONS-5010
Positive
Jun 1, 2026
On June 1, 2026, Outlook Therapeutics announced it had resubmitted its Biologics License Application to the U.S. Food and Drug Administration for ONS-5010/LYTENAVA, an ophthalmic bevacizumab formulation for treating neovascular age-related macular...
Private Placements and FinancingRegulatory Filings and Compliance
Outlook Therapeutics Announces Registered Direct Equity Offering
Positive
May 29, 2026
Outlook Therapeutics, Inc. has entered into a securities purchase agreement dated May 28, 2026, to conduct a registered direct offering of 8,539,709 shares of its common stock to GMS Ventures and Investments. The transaction was executed under the...
Business Operations and StrategyPrivate Placements and Financing
Outlook Therapeutics Announces Insider-Backed Direct Stock Offering
Neutral
May 28, 2026
On May 28, 2026, Outlook Therapeutics, Inc. entered into a securities purchase agreement with GMS Ventures and Investments for a registered direct offering of 8,539,709 shares of common stock at $0.5855 per share, expected to raise approximately $...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission
Positive
May 26, 2026
On May 26, 2026, Outlook Therapeutics said the U.S. FDA granted its appeal after a Formal Dispute Resolution process over the December 30, 2025 Complete Response Letter for its ONS-5010/LYTENAVA biologics license application for neovascular age-re...
Business Operations and StrategyPrivate Placements and Financing
Outlook Therapeutics Launches New $100M ATM Offering
Neutral
May 13, 2026
On May 13, 2026, Outlook Therapeutics entered into a new at-the-market offering agreement with H.C. Wainwright Co. that allows the company to issue and sell up to $100 million of its common stock from time to time, with H.C. Wainwright acting as ...
Business Operations and StrategyPrivate Placements and Financing
Outlook Therapeutics Announces New Equity Financing Transaction
Negative
Apr 23, 2026
On April 22, 2026, Outlook Therapeutics entered into a securities purchase agreement with institutional investors for a registered direct offering of 16,129,033 common shares and a concurrent private placement of an equal number of common warrants...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug
Neutral
Apr 21, 2026
On April 21, 2026, Outlook Therapeutics announced that it had completed a Federal Dispute Resolution meeting with the FDA’s Office of New Drugs regarding the complete response letter issued on December 30, 2025 for its biologics license resu...
Business Operations and StrategyLegal ProceedingsProduct-Related Announcements
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
Neutral
Apr 7, 2026
On April 7, 2026, Outlook Therapeutics, Inc. announced it had submitted a formal dispute resolution request to the U.S. Food and Drug Administration following a December 30, 2025 Complete Response Letter for its Biologics License Application for O...
Private Placements and Financing
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
Negative
Mar 25, 2026
On March 23, 2026, Outlook Therapeutics, Inc. launched a best-efforts public offering of 20,000,000 shares of common stock bundled with warrants to purchase an equal number of shares at a combined price of $0.25, with H.C. Wainwright Co., LLC act...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.